Ask the Experts: Please review the mechanisms of the anticoagulant and antithrombotic medications used in the treatment of acute coronary syndrome (ACA).
Albritton S, Shuler L, Schatz K. Ask the Experts: Please review the mechanisms of the anticoagulant and antithrombotic medications used in the treatment of acute coronary syndrome (ACA). Critical Care Nurse 21:75-77, 2001.
Characteristics of 1514 Hypertensive patients at high coronary risk, The VALUE Trial.
Kjeldsen SE, et al. for the VALUE Trial Group. Characteristics of 1514 Hypertensive patients at high coronary risk, The VALUE Trial. Blood Pressure 10:83-91, 2001.
Doefetilide: A new Class III antiarrhythmic for the management of atrial fibrillation.
Diaz AL, Clifton GD. Doefetilide: A new Class III antiarrhythmic for the management of atrial fibrillation. Prog Cardiovasc Nur 3:6-29, 2001.
Grapefruit juice-drug interactions: Not just pulp fiction
Clifton GD. Grapefruit juice-drug interactions: Not just pulp fiction. Cardiovascular Reviews and Reports 22:11-14, 2001.
GUSTO V: The bottom line of fibrinolytic reperfusion therapy.
Verheugt FWA. Commentary. GUSTO V: The bottom line of fibrinolytic reperfusion therapy. Lancet 357:1898-1899, 2001.
Ischemic nephropathy.
Tuttle KR. Ischemic nephropathy. Curr Opin Hypertens Nephrol 10:167-173, 2001.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, et al. for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-859, 2001.
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
Topol EJ, Califf RM, Van de Werf F, Wilerson JT, and the Gusto V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357:1905-1014, 2001.
Sex differences in uric acid and risk factors for coronary artery disease.
Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 7:1411-1414, 2001.
- Options :
- View Article Map